Advertisement

Topics

JPMorgan belässt Roche auf 'Overweight' - Ziel 300 Franken

02:31 EDT 17 Apr 2018 | FinanzNachrichten

Die US-Bank JPMorgan hat die Einstufung für Roche auf "Overweight" mit einem Kursziel von 300 Franken belassen. Die Studiendaten des Pharma-Konkurrenten Merck & Co. für ein neues Medikament legten...

Original Article: JPMorgan belässt Roche auf 'Overweight' - Ziel 300 Franken

NEXT ARTICLE

More From BioPortfolio on "JPMorgan belässt Roche auf 'Overweight' - Ziel 300 Franken"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...